TG Therapeutics, Inc.
S&P 600
$53.89
-2.71%
Delayed · cached 15 min
Fair value analysis
TGTX
TG Therapeutics, Inc.
$53.89
Close used for this calculation
$44.28Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
65/100
Quality radar
Consensus fair value
$44.28
Above FV▼ -17.8% against the close used
Model range $12.73 – $83.10
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$12.73Fair value$44.28Bull$83.10
FairClose
52-week traded range
52W low $26.9452W high $59.06
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
TG Therapeutics, Inc. closed at $53.89, 21.7% above the consensus fair value of $44.28 drawn from 6 valuation models.
Financial DNA score 65/100 — Strong. P/E of 19.5x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$54.98
+2.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
P/E Fair Value
$55.40
+2.8%
EPS × 20x (sector P/E)
EPS=2.77, Sector P/E=20x
Peter Lynch (PEG)
$83.10
+54.2%
EPS × Growth% (PEG = 1 is fair)
EPS=2.77, g=30%
EV/EBITDA
$12.73
-76.4%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=123.38M
Reverse DCF
$53.89
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 6.8% | Historical: 40%
Margin of Safety
$41.39
-23.2%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=55.19, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.